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ABSTRACT 
The next project is born with the aim of analyzing the company AB-Biotics, a company 
in a sector of expansion as it is biotechnology. The purpose of this is to know all the 
details of the company, with the help of financial and economic analysis in order to obtain 
what is the current situation of the company. First we made a study of the sector in which 
the company resides as well as the changes in this. After we focus on the economic 
analysis and financial aspects of the company as well as of the evolution of the business. 
Finally, presents the results of the study leading to the conclusion that after a few years 
difficult the company begins to improve their results and profitability although it is 
recommended that the company pay attention to its funding strategy. 
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1.INTRODUCTION  
The present work is based on the study of a company of the Alternative Investment 
Market which was born with the purpose to provide financing to small and medium-
sized enterprises with the aim of providing an opportunity for expansion at a critical 
moment of the market, as it was in 2006. In view of the high volume of this type of 
companies in Spain, the study to be carried out is an SME located in this market. AB-
Biotics is the chosen company that is characterized by being in a growing sector as is 
the biotechnology 
Then there will be a deep financial and economic analysis with the objective of obtaining 
which is the current situation of business as well as their problems. To carry out the 
Project, we have differentiated the work in three parts. 
First, we will analyze the environment, with a light study of the sector which is followed 
by all the features and historical evolution of AB-Biotics. 
 
Secondly, it will focus on the economic and financial study which analyzes with more 
detriment because it is the basis of study.  In this section, we will analyze the balance 
sheet and will be carried out different ratios that help us to see the situation in which the 
company is. The data that have been chosen, have been for the past four years that 
have been able to get the annual accounts, these are, 2012 to 2015. 
Thirdly, a study is made of the evolution of the business, which will discuss the profit and 
loss account and the profitability that is obtained from the company. Finally, will present 
the conclusions of the analysis. 
2. METHODOLOGY 
To carry out the objective of the study, we have organized in three phases.  
The first phase focused on a great search for information with the aim of understanding 
better the company.  For this, it has been structured in two parts: a light study of the 
sector of the biotechnology and a deep study of the company, which consists of its 
activity, organization and historical evolution. 
The second phase is the most important due to the work is based with this phase. The 
second phase is the most important because the work is based with this phase. To do 
this, an analysis is made of the economic and financial structure of the enterprise, as 
well as ratios are used to know the situation of the company. First we will analyze the 
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economic structure as well as its solvency and liquidity, then a study of its financial 
evolution and debt ratios is made 
The next step is the evolution of the business where profit and loss, with this analysis is 
intended to see economic developments regarding the passing of the years. Focuses in 
two parts, first analyze the profit and loss account and then a study is performed on the 
returns, both economic and financial. 
Finally after making the previous study commented, it will seek to conclude which is the 
situation that the company is and to give a vision of the future that is expected of it. 
3. THE FIRM: ACTIVITY, MISSION, VISION AND EVOLUTION 
3.1 Sector:  
The company will analyze operates in the sector of research and experimental 
development in biotechnology. Thus, according to Agro-Bio (Association of agricultural 
plant biotechnology) is understood as biotechnology the set of techniques, processes 
and methods that use living organisms or their parts to produce a wide variety of products 
for specific uses. This is applied to human health, industry, environment, or agriculture.  
The biotechnology sector in Europe continues with a trend of growth and expansion as 
says Oliver, especially within the sector, the scope that led was the biomedical, as we 
can see in the graphic 1. 
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Graphic 1: Distribution of the biotechnology sector according to its scope. 
 
                                        Source: Biocom AG, 2015. 
Last years, ASEBIO affirms that the evolution of the sector of Biotech, which is as they 
name the companies inside the biotechnology, has experienced a big change in Spain. 
The invoicing of this has been increased by 8 percentage points between 2008 and 2014, 
as we can see in graphic 2. 
 
Graphic 2:Growth of the sector Biotech in Spain 
 
                                                                Source: Barredo, 2016 
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The year 2008 this sector only accounted for the 2.98% of the gross domestic product 
(GDP). The report highlights the great evolution in the turnover of enterprises in this 
sector because 6 years later, exactly in 2014, the weight of the sector reached 10.35% 
of the GDP. An unthinkable fact in 2008, as we can be seen in Chart 2, the contribution 
of the biotechnology sector is approximate to tourism that is situated in 10.9% in the year 
2014. For years, tourism has been one of the sectors that has most contributed to the 
GDP, these data are encouraging to create a change in economic structure in 
Spain. Currently, Spain is a leader in personalised medicine and in the development of 
innovative drugs for the treatment of cancer, Alzheimer disease, autoimmune diseases 
and infectious diseases, which are among the first ten European countries in the 
development of drugs. 
 
Graphic 3: The Biotech sector opposite the tourist. 
 
      Source: Barredo, 2016 
 
3.2 Who is AB-BIotics? 
According to the web of AB-Biotics, it is a Spanish company created in Barcelona in 
2004, leader in biotechnology and whose main activity is diversified in two business 
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areas based on the research, development, protection and distribution of own 
biotechnological solutions and exclusive. 
The company has an innovative philosophy and it has an own know-how that allows to 
develop cutting-edge products that bring to the market a high added value. AB-Biotics 
projects offer to the pharmaceutical and food sector higher efficiency products which help 
to improve people's health as well as it can contribute to the reduction of  health costs. 
 
The mission of this, is to improve the health and welfare of the people through the 
development of products and the provision of services that help to support a healthy life 
and prevent diseases. 
Its vision is to establish a standard in the European Biotechnological industry offering 
value and profitability. As well as it facilitate innovative products to improve the health of 
the people and provide diagnostic information tools to health professionals to facilitate 
the control and the prescription of their patients. 
The company has focused its activity in research and development of innovative 
products in the areas of personalized medicine and functional ingredients to be 
established in the coming years in a world reference in biotechnology and genetic 
research. Currently, AB-Biotics seeks synergistic collaborations with other companies 
(such as for example pharmaceutical or food companies) to jointly develop new 
solutions, as well as continue with the search for partners interested in licensing its 
products to market them into new markets. 
Today, AB-Biotics is internationally renowned and pioneer in the área of biotechnology 
micro biome, probiotics and personalized medicine. In last two years it has been able to 
sign trade agreements with different partners at the international level. Marketing its 
products in 38 different countries. 
 
3.3 Organization of firm                     
The business model of AB-Biotics is based on the coordination of external networks of 
production and distribution          
and in the management of the innovation of form open by a powerful and qualified 
scientific group of the company. AB-Biotics has marketable products derived from their 
two technology platforms. 
 
Until 2012, the company had three lines of business, but is this year where the company 
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designs a new organizational structure with two main areas of business thus eliminating 
its third area: “AB-Biotics quantum & r & d services” aimed at providing research and 
development services for other companies, mainly in the food and pharmaceutical 
sectors. 
So in 2013, the company focuses on two areas, placing the development of business in 
the center of activity and keeping the innovation processes that make up the core 
business, which refers to the activity capable of generating value and that it is necessary 
to establish a competitive advantage to the organization. At present,the two areas that 
form the company are: Ab.genotyping and AB-Biotics functional ingredients. 
The first area is known as AB-GENOTYPING which focuses on the development of 
genetic analysis to elaborate studies of pharmacogenetics, which is the discipline that 
studies the variability of response to drugs in different patients depending on their 
genetics. That is to say, it studies the way in which patients respond to different 
treatments and drugs according to their genetic heritage. The purpose of this is to offer 
physicians more information about the most effective treatments and the most suitable 
dose for each patient known as personalized medicine. The first product released by the 
company was Neurofarmagen, a DNA chip that saliva analysis allows to assess 
the predisposition of the patient to respond to the most commonly used drugs in the 
treatment of neuro psychiatric illnesses such as depression, schizophrenia, bipolar 
disorder or epilepsy. 
The second area is AB-Biotics ingredients functional where is the activity of the company 
focused on the development of functional ingredients to improve the health of people, 
especially probiotics and other nutraceuticals for application in functional foods and 
supplements. It is functional ingredients for the prevention and treatment of a wide range 
of diseases, from cardiovascular diseases to colic infantile, among others. 
This market is constantly growing: it is expected rhythms of two-digit annual growth over 
the next 5 years, due to the higher incidence of chronic diseases and the progressive 
aging of the population, who have raised awareness in society about the importance of 
bringing a lifestyle and a healthy diet. Added to this are the documented positive effects 
of probiotics (live microorganisms that have important health benefits), and the growing 
trend in the implementation of preventive treatments. We include in this area all 
probiotics, for example, AB-LIFE which is intended to improve cardiovascular health or 
AB-FORTIS used for child cognitive development. 
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The company is listed on the MAB since 2010, their products are currently marketed in 
North America, Europe, Asia and Latin America. Specifically in 38 countries. 
 
3.4  Historical  evolution 
 AB-Biotics S.A was founded in 2004 in Barcelona but until 2010, we do not get detailed 
information of the company. It is in this year, particularly in the summer of 2010, is where 
we find more information of the company and it is in this moment when the company 
enters to form part of the Alternative Investment Market (MAB). Thus, the first company 
with headquarters in Catalonia that is listed in the MAB. The company, is negotiated in 
the segment of expanding businesses of the MAB under the Code ABB. 
Society considered as a start-up, this type of company is defined as a new company 
which has a great potential for growth and, occasionally, a scalable business model. In 
addition, To others it is considered a risk capital company, in 2010 Bonachera, one of 
the largest shareholders in the company, argued that "We are a project of risk capital 
and therefore we want to offer a high-yield investors".  
At the time the company is incorporated in the MAB, creates different capital increases. 
Motivated by the entry on the stock exchange, the company took the opportunity to 
increase the value of equity position and attract money to invest in projects or even to 
pay debt.  
In this period, the society was the presentation of a probiotic solution whose purpose 
was to treat and prevent cardiovascular disease by reducing the level of cholesterol. The 
product called AB-LIFE, would come to market a few months later. Also note an 
important agreement with laboratories Rubio, who would help the marketing of one of its 
products at the national level. The product is the Neurofarmagen TDAH which is used 
for the disorder attention deficit hyperactivity. Also provide a right to preferential option 
laboratories Rubio to granting rights of distribution exclusively for Germany, Netherlands, 
United Kingdom, among others. 
 
The most notable incident took place at the end of this year with the acquisition of 
Quantum Experimental S.L, company specialized in providing research services and 
product development to other companies in the pharmaceutical sector, medical cosmetic 
and food, located in Madrid. According to press releases from the company, the aim was 
to create a synergy between the two companies and get a greater optimization of 
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resources and complementarities of activities to offer an integral service to the market, 
as well as to accelerate the marketing of own products. In addition the company in 
Madrid, was already in international markets with which was a business opportunity to 
expand more easily. 
In April 2011, the Universitat Autònoma de Barcelona informs an extension of 1.43 million 
euros subscribed entirely by members of the Quantum Experimental S.L company 
representing 8.3% of AB-Biotics. So, with such an increase is financed the acquisition of 
the company. On the other hand, the Catalan company move forward with its strategy of 
growth thanks to the purchase of the madrilenian society who is already in international 
markets. To support internationalization, the company launched a new extension with 
the purpose of the preparation of a business plan to expand to countries like United 
States, United Kingdom, Germany and others. The contribution of the plan was 
exceeding 400 thousand euros. 
After the plan in 2011, the following year the company focuses on settle your 
comprehensive business databases, looking for and obtaining new licenses, new 
countries where they market their products as well as the introduction of new distributors 
such as Lacer Farma or Leti S.A.V. In these years, the entity manages to enter markets 
Moroccan, French, Chilean, Venezuelan or Mexican, among others 
Highlight a contract with Almirall, S.A., a company through which the pharmaceutical 
promoted exclusively products of pharmacogenetics. This AB-Biotics will address 
effective products sales, while Almirall will design and implement strategies of 
communication and marketing them. In this way, both companies will collaborate in the 
promotion and marketing of Neurofarmagen. 
Another highlight of 2012, is that at the end of this year the company decided to change 
its internal structure and focus on two main areas of business, thus maximizing its 
efficiency and the development of business-oriented.  
Therefore decided to sell its subsidiary Quantum Experimental, S.L to Nagano Business 
society. With this sale, was the focus in the marketing of their products through licensing 
agreements. 
 
Moreover, society conducted a capital increase open the MAB allowing to capture 
4.309.881,40. This marked the entrance of new shareholders, highlighting Almirall S.A. 
and the Catalan Institute of Finance (IFC). The captured capital was intended largely 
earmarked to continue funding the international expansion of AB-Biotics in the context 
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of the new business created because of the change of structure plan. The entry of 
Almirall, allowed to enhance the commercial expansion of its products. With the sale of 
Quantum and the expansion of 4.3 million, the society was facing a year 2013 with an 
important strength, both financial and shareholder. 
In 2013, after the transmission subsidiary of Quantum services and a series of relevant 
commercial advances in the previous months, the company was motivated to adopt a 
strategic shift that gave place to an update of the business plan. This time was based on 
the focus of its main lines of business: Functional Ingredients; and Genotyping explained 
above.  
 
This year, marked the start of a consolidation of the process of internationalization as 
well as the updating of the internal structure of the company. Highlight a new capital 
increase amounting to 1.12 million euros, being society Seed Capital the main subscriber 
acquiring 5.2% of the shares of the company. . This capital will be used to finance various 
programs of research within the two business lines, as well as to the international 
expansion of the Neurofarmagen product. 
 
This year continue to patents and agreements with different companies. Business plan 
began to give fruits even improved the estimated results thanks to the centralization in 
the two areas of business. But this year there was a reduction of activity with which the 
company not could carry out all their plans and invest as planned. To avoid resources 
by criteria of profitability and idle, it had to invest their assets. 
 
The period of 2014, is marked by licenses, since this year 29 license agreements are 
created with new business partners. The company gets presence in 22 countries with 
which the process of internationalization is giving its fruit. Note an increase of marketed 
products, as well as closed contracts allowing you to launch their products in new 
countries or even contracts with other companies for the development of new products 
in the area of functional ingredients. 
 At this point, the income generated by the company are in four geographic areas. These 
areas are as AB-Biotics divides its business and are: Europe, Latin America, Asia Pacific 
and North America-MENA. This diversification in revenue allows you to minimize the 
seasonal nature of sales. 
 
AB-Biotics reports a significant fact of the Constitution, on 23 December 2014, of the 
subsidiary “AB-Biotics Research Services, S.L.” in which the company is the sole 
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member constitute a contribution valued at four hundred thousand euros. The subsidiary 
aims to activities of research and development and provision of consulting services in 
the field of biotechnology and genetics, as well as licensing of manufacture, patents, 
formulae, trademarks and other intellectual or industrial property rights and the 
exploitation of these rights. The subsidiary Food Genomics, S.L.U. in order that company 
to participate in the program of acceleration Prometheus is also reported. 
 
The year 2015 is complete with a subscription of 27 new license agreements which 
together with the previous years have allowed to have a presence in 29 countries. 
Increasing your marketing in 7 new countries. In addition, the company started in about 
50 countries regulatory processes. Also noted the favorable evolution of the company, 
who suffers a considerable increase of their income for the year 2014. 
 
An important agreement was that was signed between the company and Experimental 
Quantum, S.L., which consists in the transfer of results and trading exclusive of a product 
for the treatment of peri-implantitis, for whose acquisition the company paid as 
compensation rights of credit of 1,500,000 euros owed by the firm Business Nagano, 
S.L. and 478.000 euros owed by Experimental Quantum society , S.L, and 20% of the 
net sales of the product only during the first two years of its marketing, with a minimum 
of the same set. 
 
The company faces the future with the aim of further increasing the number of 
agreements for development and marketing of licensed products. As well as the 
transformation of the company to secure a biotech start-up.  
 
The company's latest report, argues that the development of AB-Biotics business model 
is at an early stage of value creation, through research, product development and the 
distribution of licenses. Through the transfer of knowledge, the company has already 
managed to reap the first fruits of their work, thanks to its international expansion with 
the distribution of more than 40 licenses of exclusivity. The company is currently in a 
phase of growth, which is also shown with obtaining patents for various products around 
the world, such as the "AB-Dentalac" and "ABFortis". Following this strategy, AB-Biotics 
could be used in the medium term these efficiencies to get take advantage of economies 
of scale, as well as an improvement in its structure of variable costs. 
 
In this sense, the figures from the company have already proved a positive trend with an 
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increase in the profit for the year as you can see in the losses and profits in annex 2. But 
the company also has more potential since collaboration with various partners and other 
business partners, offer the ability to increase their supply on the market. 
 
4. FINANCIAL ECONOMIC DEVELOPMENTS 
The economic-financial evolution of the company will be realized of last 4 years, this 
period is comprised from 2012-2015. We will differentiate this part of the study in two, 
first we will analyze the AB-Biotics economic structure, and on the other hand there will 
be realized the study of the financial structure. 
 
In the first place, we will examine the economic structure of the company that will focus 
on analysing the assets, namely, the goods and rights with which the company account. 
The structure is divided into the permanent assets (assets Non-current) and current 
assets. The difference among these is that the permanent, ensures the life of the 
company and the assets are the product of the production cycle and  the business of the 
company. Within this analysis we will study the solvency and liquidity of the company. 
 
Secondly, we will focus on the financial structure where we will analyze the passive place 
where the sources of financing of the undertaking are collected. With this, we can 
determine how the company is financied Liabilities are equity (partners money) current 
liabilities and non-current (agents external to the company in the short and long term 
respectively). 
 
Basically, the realization of this analysis carried out to collect financial data from the 
company that will be used to compare the difference existing among the various groups 
that form the financial structure and to observe the changes presented by the various 
operations of the company. This analysis helps to the decisión making 
 
4.1 Anlysis of  economic structure 
To analyze the economic structure, we will use the graphic 4 that showing the evolution 
of departures that forming the asset. At a glance, we can see where is the greater weight 
of the company, this is concentrated in the asset is not current. 
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Graphic 4: Economic structure 
   
                              Source: Own elaboration from the annual accounts. 
 
The tendency of the goods and rights of the company is downward we see that the asset 
will reducing moderately until the year 2015, this is reaffirmed by marked the total asset 
trendline on the graph. This line is down which means that the value of the asset is 
increasingly less. Mainly, this trend is due to that the company has had a change in the 
active current that has been significantly reduced. On the other hand, the non-current 
asset does not suffer significant changes since this is around 10 million in the period 
under study. But we noticed a few light promotion in 2012 and 2015 with regard their 
past, variations that we will explain later. 
 
 
To explain the sudden reduction of the current assets, from 2012 to 2013, we must 
understand because it has that value in the current assets in 2012. That year, cash and 
equivalents have a percentage close to 30% of the total of current assets, but in terms 
of total assets refers this percentage increases to 66%. So, this is the account with major 
proportion within all the assets. Thus,  the study will focus on cash because with a year 
of difference this item is reduced by 20% in the active current and is the most significant 
change in the balance of the company, as you can see in table 1. 
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Data table 1: Evolution of the cash and other liquid assets equivalent. 
   2012 2013 2014 2015 
  Cash 
and other equivalent liquid 
assets 
 
4.754.569 1.273.959 1.038.224 604.536 
% respect to current 
assets  
 
28,71% 8,51% 7,35% 4,38% 
% respect to total assets  66,45% 30,31% 26,32% 19,79% 
                                   
                                            Source: Own elaboration from the annual accounts. 
 
As we can see in table 1, the values of cash in 2012 were about 5 million instead in 2013 
the company has just over 1 million euros.  The amount of cash in 2012 is due to the fact 
that the firm at the end of that same year sold the subsidiary Quantum with the purpose 
of making a new organizational structure of the association. In contrast, this is not the 
main cause for the company to have abundant cash, if not that really, the increase in 
cash is given by a capital increase of more than 4 million euros. This increase was 
intended for a new business plan focused on financing the international expansion of the 
company.  
So, both reasons are causing that the company had this abundant amount of cash. 
 
In 2013, the company met with an excess of cash which was used for the habitual 
consumption by current spending and for investments in long-term financial instruments, 
this account growing 631miles euros from the year before as shown in annex 1. These 
have been the causes for which the company has been reduced its cash, and at the 
same time, the departure of current assets. Initially the company had no intention of 
investing in these instruments, since enlargement was going to be dedicated to the 
activity, but the volume of business in 2013 was reduced. Therefore, the Organization 
was obliged to invest the surplus in long-term investments by question of criteria of 
profitability for the company and thereby avoid own idle resources. 
 
Except for this remarkable change, the company continues with negative trend in current 
assets, but this is moderate, as well as the cash. The changes are motivated by the 
normal activity of the company and supported by the favorable evolution of the activity 
of the corporation. 
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Secondly, we will focus on the change of the asset are not current in two points, in 2013 
and 2015. The variation of 2012 to 2013 was due to investments in instruments that have 
been made with the treasury as well as by an increase in the rights of charge for deferred 
taxs. In conclusion, the current assets is modified by reducing the cash and the no-
current assets is modified due to the investment of this cash in this type of financial 
investments and in the deferred tax collection rights. 
 
Highlight, a second change of non-current assets, which is not so noticeable, but 
interesting. This is between 2014 and 2015 which is caused by an increase in  Intangible 
assets produced by research and development activities as well as investments in 
patents and software elements. This item is increased 59% compared to 2014, as a 
result of an acquisition of a technology for a new treatment. 
 
With the analysis of the assets of the company made, we will carry out a study of liquidity 
and solvency. First we will focus on its solvency helped with the rolling fund and then will 
be the liquidity of this company. 
In the graphic 5, we will find the evolution of the Fund of maneuver that as can be seen 
every time is less. Have a positive rolling fund indicates that the company is solvent in 
the short term. With other words, a company is solvent if when it sold all of its holdings, 
it charges the debt of all its customers and also with their cash, it is able to meet all debts 
that the company maintains short-term, as for example, debt with short-term credit or 
debt with suppliers.  
 
Graphic 5: Evolution of the rolling fund 
 
                                                                           Source: Own elaboration 
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In the case of the probiotics company, we can say that the company can cope with short-
term debts with its active power, since it has a positive rolling fund. But we must bear in 
mind that not always a positive rolling fund is a good result, since an excess can lead to 
problems of efficiency. The rolling fund is the difference between the current assets and 
current liabilities. This is: 
       CA-CL = Rolling fund. 
We believe that the best way to see this difference, is carrying out a chart that compares 
the current assets and current liabilities. The difference between the columns is the 
rolling fund. 
Graphic 6: Difference among current asset and current liabilities 
 
                                            Source: Own elaboration from the annual accounts. 
 
Graphic 6, shows the current assets and the current liabilities in different years that we 
are studying. As you can see, all the years the company can cope with debts in the short 
term (current liabilities) with its current assets since is clearly observed that the current 
assets is greater. It should be noted that the first year, the company can cope with its 
passive obtaining a significant surplus, this is of more than 5 million. The rest of the year, 
has a minor over where almost gets the active current and current liabilities balance by 
2015. So we can consider that with the passage of time, the company has managed to 
take advantage of its resources while being close to the balance isn't a positive any 
adversity the company may not be solvent. For example, due to lack of payment of their 
customers, the company would have solvency problems.  The year 2012, the surplus is 
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high with which we can consider that it is not positive for the company to obtain such a 
result. In graphic 6, we have the composition of the balance of this year, as well as the 
result of the rolling fund. 
The year 2012, the surplus is high with which we can consider that it is not positive for 
the company to obtain such a result. In Figure 6, we have the composition of the balance 
of this year, as well as the result of the rolling fund.  
Graphic 7: Balance 2012 
  
                                     Source: Own elaboration from the annual accounts. 
 
 
You can see how with the rolling fund that gets this year the company has the power to 
deal with all of your debts in the short term, it would even be able to pay debts in the long 
term because you can see how the rolling fund is greater than total liabilities. This excess 
of cash leads to a loss of profitability caused by having idle resources, that is to say, 
resources that the company does not take off the optimization. As we have explained 
above this value in the active current is given by the sale of Experimental Quantum and 
capital increase.  
 
At this point, we have studied if the company is able to meet its debts, then, will make 
the ratio of liquidity which measures liquid so that it is the company, i.e. the business 
capacity to cope with short-term liabilities without difficulties. It shall be deemed that a 
company has an ideal result when its liquidity ratio exceeds 1. As we confirmed in graphic 
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8, the company would be in an ideal situation, since in the period studied, the company 
has one ratio greater than 1. 
 
Graphic 8: Evolution of current ratio 
 
                                                                            Source: Own elaboration. 
 
According to the graph 8, and knowing that the ideal result is 1, we can argue that the 
company has a large deviation upward since it exceeds the perfect result, except in 2015 
having a value of 1.02 and could consider that the company may have liquidity problems 
in the future if this result continues the negative trend as firm would have little margin for 
error in situations of non-payment. Confirming what was said in the rolling fund, the 
company these past 3 years has had idle resources since the value of the ratio is too 
high, even reaching 4. Thus, the company has wasted its resources during the past 3 
years since these resources could have obtained a return. These data tend to indicate 
the existence of a productivity problem. The purpose of this study is to give an overview 
to the company regarding its liquidity and thus be able to take steps to solve future 
problems. 
 
4.2 Financial analysis 
After the analysis of the economic structure, we will carry out the study of the financial 
structure of AB-Biotics. This structure indicates which are the resources that have the 
company to finance the previously analyzed economic structure. These forms of finance 
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represent a cost to the company. In addition, we will study the way in which the company 
is indebted, from the debt ratio.  
 
First of all, look at the composition of the financial structure of the company. To do this, 
use the following graph which shows the three main headings: net equity, non-current 
liabilities and current liabilities as well as their amount. 
Graphic 9: Evolution of liability and equity composition. 
 
                                   Source: Own elaboration from the annual accounts. 
 
 
At first glance, it is understood that the most important departure of AB-Biotics is equity. 
Although this will reduce with over the years because of the result of the company and 
the previous years which remain negative for years as it can be seen in annex 3. On the 
other hand, not current liabilities is that its value remains constant throughout the years, 
instead the current liabilities has various changes which we will discuss.In terms of 
equity, its trend is downward, but reduction is moderate with the passage of the years. 
Not include any point since every year the reduction round 1 million euros. This reduction 
is given by the constant losses suffered by the company and its accumulation since the 
company has not obtained benefits in recent years. Own funds accounted for around 
60% of the total of the financial structure of the company. Thus, we can say that the 
company is financed by its own funds. 
 
We know that a company must be dissolved when losses exceed 50% of the issued 
capital. Victor García montero explains, that the causes of compulsory dissolution are 
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regulated in article 363 of  
the Law of Capital Companies  if the loss leave reduced the equity to an amount less 
than half the share capital the company must be dissolved. Faced with this situation, we 
find different solutions that are approved at the Annual general meeting (AGM), AB-
Biotics opted for the realization of issue of new shares. Thanks to this issue, the company 
remains in operation. As shown in annex 3, the departure of share premium each year 
is higher derivative of the capital increases made by the company. These increases are 
for purposes to the activity of the company, as well as prevent the dissolution of this. 
Without this number, we could say that the company would suffer risk of dissolution in 
the absence not to take another series of measures. 
 
The non-current liabilities represents around 25% of total liabilities of the company during 
the period. Their departure is based on long-term debts, such debts incurred the vast 
majority with credit institutions as you can see in the company balance sheets in annex 
1. This has no remarkable changes. 
 
On the other hand current liabilities has various changes. These fluctuations are related 
to commercial creditors and other accounts to pay. The departure of current liabilities is 
formed of 3 great accounts as we can see in the balance sheet in annex 1, where the 
weight of current liabilities is concentrated only in 2, these are the accounts of creditors 
and debts short term. If we look at the graphic 10, we can see how current liabilities 
fluctuates in a similar way to trade creditors and other payables, this item includes 
suppliers, creditors or Treasury debts. 
 
So, the departure of creditors and the tendency of this is related to the business activity. 
In 2013, it undergoes a reduction linked to the decrease in activity. The two following 
years there were increases in this account due to the growth of the activity of the 
Company, although it should be noted the increase in 2015. So, we find a direct 
relationship of current liabilities to their creditors and simultaneously with the activity of 
the company. To greater activity greater consumption, and thus greater are against 
suppliers, creditors, or public finance needs. 
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Graphic 10: Accounts of current liabilities. 
                                         
Source: Own elaboration from the annual accounts 
 
Following the financial part, we will focus on the form of borrowing that has the company. 
So we made a line graph that shows the proportion of debt that supports the company 
in which is observed that indebtedness is higher with the passage of time, although he 
suffered variations in these 4 years. We focus on the total indebtedness, an ideal 
percentage could be between 40-60%. Low levels of indebtedness are that the company 
may be incurring an excess of idle capital, and loss of profitability. On the contrary, high 
values would mean borrowing too much. With this situation the company can have a 
decapitalization and with it a loss of autonomy against third parties. Thus, as shown in 
the graphic 11 can establish the entity subject to the 3 first years of study, instead in 
2015, the company has a high percentage of debt. His percentage slash 95% with what 
the company is at a critical point since this result means that liabilities are close to being 
equal to the equity and has risk the company suffer a decapitalization. The cause of this 
high percentage is basically by an increase in borrowing in the short term by 30% where 
this growth is focused on suppliers and creditors of the company. 
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Graphic 11: Evolution if indebtedness 
 
                                                                           Source: Own elaboration. 
Although the latest data of the company assumes a negative by its high indebtedness 
and whereupon a strong dependence on external financing. Long-term debt is still 
greater than short-term, data positive for the borrowing since it is recommended that 
happen as well. 
5 ANALYSIS OF BUSINESS EVOLUTION  
The first step to analyze the evolution of the business will see the company's internal 
data. The second step, will be held later with the help of a series of ratios with the aim of 
achieving the profitability of the company and the shareholder. These data help 
determine the health of a company and obtain its evolution. Variables to obtain yields 
are important to the company, since they are directly related to the decisions taking the 
organization. To obtain a certain profit is assuming a risk that must be taken into account 
for the company, since it must be clear that greater profitability is related to an increased 
risk. 
 
5.1 Business evolution   
As we have already mentioned, we will first discuss those most important items within 
profit and loss. To do this we have helped us a graphic.  
 
According to the graphic 12, the trend that follows the amount of business is up as well 
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as so are costs, since these parameters are interrelated, how much greater volume of 
business increased costs are. The amount of business has a turning point in 2013, 
moment in which the company makes a change in its organizational structure. This 
change, meant for the company strengthened the area of business development through 
contracts and agreements with companies of reference in the market both nationally and 
internationally in order to achieve its internationalization process. Thus, revenues from 
sales of products and services were decreased by 38%. From 2013 the company grows 
moderately because of internationalization which began to be implemented vigorously 
year, later said the company sees increase their volume of business through this process 
that involves among others major agreements and licenses. 
 
Graphic 12:Profit and lost 
 
                                    Source: Own elaboration from the annual accounts 
Analyzed in detail some important aspects of the income of the exercise, then we will 
see which is the trend that follows the company over the years. That is to say, the 
evolution of its result. We can say that the trend that still is positive, while the result for 
the year is negative and the company still failed to get a positive. On the other hand, the 
results are favourable since the company increasingly approximates more results 0. The 
difference from the first year that we looked at and the last is about 1 million euros less 
than negative result, whereupon the institution throughout the years is getting to improve 
your outcome. As we have seen in graphic 10, this improvement in the result is basically 
that the turnover is higher since other expenses have not suffered big changes, as it is 
the personnel expense. 
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Graphic 13: Evolution of the income account. 
 
                                        Source: Own elaboration from the annual accounts 
 
Up to here the study of the financial structure where we find large deficits in the company 
to cope with a positive improvement of their results. Even significantly increasing its 
turnover society does not reach for optimal results. 
An important fact to highligth, is the share premium, as we have previously discussed 
thanks to these contributions in kind is achieved not close the company and that this still 
in operation. Since observing the annual accounts, Annex 3, we notes that the income 
of the exercise is greater than net equity if not rises with the share premium. 
Then we will focus on the study of the profitability of the assets of the company and 
financial profitability or shareholder. For this, we will use return on assets (ROA) and 
return on equity (ROE) respectively. First we will make the analysis of the ROA and then 
the ROE, since ROA is a function of this. 
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5.2  Profitability analysis   
To measure the profitability of the company we use the ROA, and as we can find in the 
graph 14, the company counts with an ROA negative but with positive trend near 0. Thus 
we can say that the company does not get economic benefits with respect to its total 
capital. That is to say, the company still does not have a profit. The company has few 
assets that are not being used or managed correctly. Currently, the profitability for every 
euro invested in the company is negative,for example,  in 2015 for each euro invested 
one obtains a loss of 0.08. The capital that the company was investing in production yet 
produces no benefit. 
 
Graphic 14: Evolution of ROA 
 
                                                                           Source: Own elaboration  
 
In general, we can establish an acceptable ROA, one whose value is greater than 5%. 
The firm is far from such a result so we can say that with assets owned by the company, 
this fails to get the maximum profitability. We know that the company does not make the 
most so we will perform the decomposition of this ratio. Normally, a negative ROA is 
accompanied by high levels of debt that magnify the effect of the ROA negative. The 
ROA decomposes into margin and rotation. The formula that follows is as follows: 
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This means,      𝑅𝑂𝐴 = 𝑀𝐴𝑅𝐺𝐼𝑁 ×  𝑅𝑂𝑇𝐴𝑇𝐼𝑂𝑁 
 
To see the reason for the improvement of this ratio, we use table 2 showing us the 
evolution of the margin and rotation. 
Data table 2: Decomposition ROA 
 2012 2013 2014 2015 
ROA -12,129% -11,142% -9,929% -8,040% 
MARGIN -122,367% -203,622% -85,859% -32,173% 
ROTATION 9,912% 5,472% 11,564% 24,991% 
CHECK ROA  = MARGIN  x  ROTATION  -12,129% -11,142% -9,929% -8,040% 
 
                                                 Source: Own elaboration. 
 
The two concepts are suffering a considerable improvement in this period. The margin 
has obtained a reduction of 90 percentage points with which the company is closer to 
obtain wealth for each monetary unit. In 2015, lost 0.32 cents per euro when 3 years 
before is lost was of 1.22. The improvement is due to positive change that have 
experienced the result and the number of business that we have previously analyzed. 
Moreover, the rotation has increased 15 points from the first year analyzed at last, also 
due to the increase in the amount of business and by the slight decline in assets. Thus, 
the company has improved the number of times that the assets are converted into sales. 
On the other hand, we will analyze the profitability of the shareholder with the help of 
ROE. This shows us the fruit of the investment made by the shareholders, that is to say, 
the performance you get these by your investment. The shareholders aim to obtain a 
higher return on your investment. In the Graph 15 it can be seen that the company has 
a negative ROE. This means that the shareholders do not gain any profitability if not that 
for every euro invested lose a much, for example, 0.17 cents lost in 2015 to invest a 
euro. 
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Graphic 15: Evolution of ROE 
 
                                                                           Source: Own elaboration. 
 
Note that the curve is positive and each year this percentage is lower, therefore the 
shareholder gets less lost. So we have an encouraging fact, since if the trend continues, 
the society could get benefits in the future although the change seen in the last 4 years 
is slow. 
With the result of the asset and shareholder returns, we will compare both ratios. This 
comparison leads us to determine the most appropriate financial structure for the 
company's growth. It is what is known as a leverage effect. As you can see in graph 16, 
the ROA is better than ROE, so with this statement we know already, that the company 
has a negative leverage. In situations as well, the company could increase its debt only 
in case you have ability to increase their sales prices and manage their assets efficiently. 
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Graphic 16: Comparision ROA  and ROE 
 
                                                                      Source: Own elaboration. 
 
The following analysis we will perform, is the in-depth study of the ROE will analyze it 
with greater expense with their most significant determinants. According to the following 
formula: 
 
𝑅𝑂𝐸 = 𝑅𝑂𝐴 +
𝐿𝐼𝐴𝐵𝐼𝐿𝐼𝑇𝑌
𝑁𝐸𝑇 𝐸𝑄𝑈𝐼𝑇𝑌
 × (𝑅𝑂𝐴 − 𝐹𝐶) 
 
𝑅𝑂𝐸 = 𝑅𝑂𝐴 + 𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 𝑅𝐴𝑇𝐼𝑂 × 𝑀𝐴𝑅𝐺𝐼𝑁 𝑂𝐹 𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸  
 
𝑅𝑂𝐸 = 𝑅𝑂𝐴 + 𝐹𝐼𝑁𝐴𝑁𝐶𝐼𝐴𝐿 𝐿𝐸𝑉𝐸𝑅𝐴𝐺𝐸 
After the breakdown of the profitability of the shareholder, we will focus on leverage, 
since the ROA has been analysed previously. 
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Graphic 17: Evolution of financial leverage 
 
                                                                           Source: Own elaboration. 
 
In the graph we reinforce the thesis above commented that the company has a negative 
leverage, that is the effect that introduces the indebtedness on the profitability of the 
capital.  
 
As you can see in the graphic 16, the ROA is lower than the interest that is to say, the 
rate of return that is reached on the assets of the company, is less than the rate of interest 
to be paid the funds obtained in the loans. This creates a negative financial leverage and 
translates with that obtaining funds from loans is unproductive. 
To be ROA less to interest, the margin of leverage increases and creates a decrease in 
the ROE. As can be seen in table 3, over the years the result of ROA improves, as well 
as the cost of the debt, therefore the margin of leverage suffers an improvement in these 
years. 
For the part of the degree of leverage, you can check with the passage of the years this 
is near, to be a value 100%. This means, that the company is virtually financed by its 
own funds the debts of the enterprise are similar to equity of AB-Biotics.  
 
Analyzed the two determinants that form the financial leverage, we can conclude that 
the improvement produced by the ROA and the cost of debt is not enough to create a 
positive financial leverage or improve your outcome. 
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So the financial profitability is suffering a positive change but the process will be slow 
since the company has managed to improve all aspects that form the ROE except the 
degree of indebtedness which has worsened in recent years. 
 
Data table 3: Descomposition of ROE 
 2012 2013 2014 2015 
ROA -12,13% -11,14% -9,93% -8,04% 
ROE -19,50% -18,22% -17,69% -17,38% 
Effective cost  = i 1,10% 2,91% 2,44% 1,91% 
Margin of leverage = ROA-i -13,23% -14,05% -12,37% -9,95% 
Leverage ratio 55,70% 50,40% 62,75% 93,78% 
Financial leverage -7,37% -7,08% -7,76% -9,34% 
Check ROE = ROA + financial leverage -19,50% -18,22% -17,69% -17,38% 
                                 Source: Own elaboration  
6. CONCLUSION      
The work was intended to provide a general overview of the company with which after a 
deep study understanding on the situation which is AB-Biotics. The company was 
presented as a venture capital company that is listed on the MAB and its main objective 
is the expansion, this means,the internationalization. In order to achieve this result, the 
society sought new shareholders to increase its capital and to invest, as well as new 
agreements in order to increase your international sales. 
 
With the various aspects discussed, the company has a turning point marked in 2013, 
where activity was reduced, but above all was because the Organization entered a new 
strategic shift at the company. This was the modification of the internal structure, which 
was based on 2 business areas focus which resulted in a positive development for the 
company. This turning point was the beginning of a massive process of expansion and 
growth of the company 
 
We have found a company with sufficient liquidity and solvency to respond to third 
parties, even improved the utilization of idle resources although if continued negative 
trend, the company could face potential economic problems. 
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On the other hand, the economic and financial profitability suffered derived improvement 
both from an increase of the activity of the company and what this entails improving the 
margin, profit or rotation. But the highlight of these results, before a noticeable 
improvement is considered that the degree of leverage should be revised by the 
company. Since increasingly has one greater data and impact on the profitability of the 
company. To improve this, society should change its way of Finance since their funding 
is basically made of own funds, and if this trend is not amended the company could suffer 
in the future a decapitalization.  
 
In conclusion, this work has been detect deficiencies of the company which is very helpful 
when making decisions for AB-Biotics 
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8. ANNEX:  
Annex 1: 
 
 
 
      ACTIVO
      ACTIVO NO CORRIENTE 10.751.946 10.175.222 10.759.004 9.407.144
   I        Inmovilizado intangible 6.718.465 4.232.961 4.072.235 4.282.345
   II      Inmovilizado material 395.441 434.559 433.318 490.657
   III     Inversiones inmobiliarias n.d. n.d. n.d. n.d.
   IV     Inversiones en empresas del grupo y asociadas a largo plazo 6.000 262.961 333.538 8.938
   V       Inversiones financieras a largo plazo 338.052 1.917.900 3.323.764 2.728.018
   VI     Activos por impuesto diferido 3.293.988 3.326.841 2.596.149 1.897.186
   VII    Derechos comerciales no corrientes n.d. n.d. n.d. n.d.
      ACTIVO CORRIENTE 3.054.997 3.944.149 4.202.641 7.154.863
   I        Activos no corrientes mantenidos para la venta n.d. n.d. n.d. n.d.
   II      Existencias 318.459 323.814 259.593 235.090
   III     Deudores comerciales y otras cuentas a cobrar 1.979.654 1.749.301 743.548 1.490.405
   IV     Inversiones en empresas del grupo y asociadas a corto plazo 11.860 36.072 14.980 276.989
   V       Inversiones financieras a corto plazo 36.129 708.696 1.825.100 359.622
   VI     Periodificaciones a corto plazo 104.359 88.042 85.461 38.188
   VII   Efectivo y otros activos líquidos equivalentes 604.536 1.038.224 1.273.959 4.754.569
      TOTAL ACTIVO 13.806.943 14.119.371 14.961.645 16.562.007
      PATRIMONIO NETO Y PASIVO
         PATRIMONIO NETO 7.124.977 8.675.348 9.947.782 10.636.815
  A1     Fondos propios   6.824.382 8.323.768 9.654.694 10.569.566
  A2     Ajustes por cambios de valor n.d. n.d. n.d. n.d.
  A3     Subvenciones, donaciones y legados recibidos 300.595 351.580 293.088 67.249
         PASIVO NO CORRIENTE 3.691.327 3.701.359 3.688.064 4.183.017
   I        Provisiones a largo plazo n.d. n.d. n.d. n.d.
  II       Deudas a largo plazo 3.591.128 3.584.166 3.590.368 4.183.017
 III       Deudas con empresas del grupo y asociadas a largo plazo n.d. n.d. n.d. n.d.
 IV       Pasivos por impuesto diferido 100.199 117.193 97.696 n.d.
  V       Periodificaciones a largo plazo n.d. n.d. n.d. n.d.
 VI       Acreedores comerciales no corrientes n.d. n.d. n.d. n.d.
VII      Deuda con características especiales a largo plazo n.d. n.d. n.d. n.d.
         PASIVO CORRIENTE 2.990.639 1.742.664 1.325.799 1.742.175
  I        Pasivos vinculados con activos no corrientes mantenidos para la venta n.d. n.d. n.d. n.d.
  II       Provisiones a corto plazo n.d. n.d. n.d. n.d.
 III       Deudas a corto plazo 1.002.643 817.691 629.356 409.132
 IV       Deudas con empresas del grupo y asociadas a corto plazo n.d. n.d. n.d. 7.044
  V       Acreedores comerciales y otras cuentas a pagar 1.975.930 891.173 696.443 1.326.000
 VI       Periodificaciones a corto plazo 12.066 33.800 n.d. n.d.
VII       Deuda con características especiales a corto plazo n.d. n.d. n.d. n.d.
            TOTAL PATRIMONIO NETO Y PASIVO 13.806.943 14.119.371 14.961.645 16.562.007
ANC AC PN PNC PC PYG
2015 2014 2013 2012
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Annex 2: 
 
 
 
 
 
 
 
 
 
 
 
      CUENTA DE PÉRDIDAS Y GANANCIAS 2015 2014 2013 2012
            Operaciones continuadas
 1. Importe neto de la cifra de negocios 3.450.467 1.632.794 818.682 1.641.606
 2. Variación de existencias de productos terminados y en curso de 
fabricación
n.d. n.d. n.d. n.d.
 3. Trabajos realizados por la empresa para su activo 1098626 745.776 448.716 1.080.402
 4. Aprovisionamientos -1.801.697 -1.042.563 -793.270 -1.411.851
 5. Otros ingresos de explotación 245.081 1.008.325 925.916 376.530
 6. Gastos de personal -1.844.678 -1.736.011 -1.465.586 -1.825.801
 7. Otros gastos de explotación -1.830.669 -1.728.763 -1.567.607 -2.188.395
 8. Amortización del inmovilizado -773.455 -770.325 -698.538 -533.925
 9. Imputación de subvenciones de inmovilizado no financiero y otras 114.678 128.498 47.187 n.d.
10. Excesos de provisiones n.d. n.d. n.d. n.d.
11. Deterioro y resultado por enajenaciones del inmovilizado n.d. n.d. -180.000 n.d.
12. Diferencia negativa de combinaciones de negocio n.d. n.d. n.d. n.d.
13. Otros resultados -10.136 10.761 248.102 -319
      RESULTADO DE EXPLOTACION -1.351.783 -1.751.508 -2.216.398 -2.861.753
14. Ingresos financieros 22.632 53.788 64.724 19.107
15. Gastos financieros -182.724 -189.853 -208.432 -93.004
16. Variación de valor razonable en instrumentos financieros n.d. n.d. -28.339 1.936
17. Diferencias de cambio 21.555 47.785 -14.821 -5.138
18. Deterioro y resultado por enajenaciones de instrumentos financieros 175.802 -434.995 -125.958 -113.004
19. Otros ingresos y gastos de carácter financiero n.d. n.d. n.d. n.d.
      RESULTADO FINANCIERO 37.265 -523.275 -312.826 -190.104
      RESULTADO ANTES DE IMPUESTOS -1.314.518 -2.274.783 -2.529.224 -3.051.857
      RESULTADO DEL EJERCICIO PROCEDENTE DE OPERACIONES 
CONTINUADAS
-1.238.041 -1.534.795 -1.812.918 -2.073.879
            Operaciones interrumpidas
      RESULTADO DEL EJERCICIO -1.238.041 -1.534.795 -1.812.918 -2.073.879
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Annex 3: 
 
Annex 4: 
 
         PATRIMONIO NETO 7.124.977 8.675.348 9.947.782 10.636.815
  A1     Fondos propios   6.824.382 8.323.768 9.654.694 10.569.566
     I  Capital 479.809 479.809 479.809 453.675
1. Capital escriturado 479.809 479.809 479.809 453.675
2. (Capital no exigido) n.d. n.d. n.d. n.d.
II  Prima de emisión 14.351.559 14.340.297 14.063.160 12.913.525
III  Reservas 30.175 30.175 30.175 30.175
1. Legal y estatutarias 4.394 4.394 4.394 4.394
2. Otras reservas 25.781 25.781 25.781 25.781
3. Reserva de revalorización n.d. n.d. n.d. n.d.
4.Reserva de capitalización n.d. n.d. n.d. n.d.
  IV  (Acciones y participaciones en patrimonio propias) -1.276.093 -1.003.486 -930.218 -652.495
  V  Resultados de ejercicios anteriores -5.523.027 -3.988.232 -2.175.314 -101.435
1. Remanente n.d. n.d. n.d. n.d.
2. (Resultados negativos de ejercicios anteriores) -5.523.027 -3.988.232 -2.175.314 -101.435
  VI  Otras aportaciones de socios n.d. n.d. n.d. n.d.
 VII  Resultado del ejercicio -1.238.041 -1.534.795 -1.812.918 -2.073.879
VIII  (Dividendo a cuenta) n.d. n.d. n.d. n.d.
   IX    Otros instrumentos de patrimonio neto n.d. n.d. n.d. n.d.
  A2     Ajustes por cambios de valor n.d. n.d. n.d. n.d.
  I   Activos financieros disponibles para la venta n.d. n.d. n.d. n.d.
 II   Operaciones de cobertura n.d. n.d. n.d. n.d.
III   Activos no corrientes y pasivos vinculados, mantenidos para la venta n.d. n.d. n.d. n.d.
IV   Diferencia de conversión n.d. n.d. n.d. n.d.
 V   Otros n.d. n.d. n.d. n.d.
  A3     Subvenciones, donaciones y legados recibidos 300.595 351.580 293.088 67.249
